Welcome to our dedicated page for Quoin Pharmaceuticals Ltd. SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quoin Pharmaceuticals Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quoin Pharmaceuticals Ltd.'s regulatory disclosures and financial reporting.
Quoin Pharmaceuticals shareholder Woodline Partners has disclosed a significant passive stake in the company. Woodline Partners LP, an investment adviser, reports beneficial ownership of 2,785,370 Ordinary Shares of Quoin, representing 9.5% of the class, with sole voting and dispositive power over all reported shares.
The position is held through Woodline Master Fund LP via American Depositary Shares, each representing thirty-five Ordinary Shares. The percentage ownership is based on 29,364,180 Ordinary Shares outstanding as of November 3, 2025. Woodline certifies the holdings are in the ordinary course of business and not for the purpose of influencing control of Quoin Pharmaceuticals.
A group of investment entities associated with Israel A. Englander, including Integrated Core Strategies (US) LLC and Millennium Management LLC, reports beneficial ownership of 2,618,595 Quoin Pharmaceuticals ordinary shares, representing 4.6% of the class as of December 31, 2025.
The group reports only shared voting and dispositive power over these shares and no sole power. They state they have ceased to be beneficial owners of more than 5% of the outstanding ordinary shares and certify that the holdings are not for the purpose of influencing control of Quoin Pharmaceuticals.
Ikarian Capital, LLC and Neil Shahrestani filed an amended Schedule 13G reporting their beneficial ownership of 211,538 American Depositary Shares (ADS) of Quoin Pharmaceuticals, Ltd., equal to 12.6% of the ADS class based on 1,683,627 ADS outstanding as of January 31, 2026.
The ADS represent ordinary shares of Quoin and are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts over which Ikarian Capital has investment discretion. The filers state the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Quoin.
Quoin Pharmaceuticals (QNRX) reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor. On February 4, 2026, she received an option to purchase 85,250 American Depositary Shares (ADS) at an exercise price of $7.37 per ADS.
The option covers ADSs, each representing thirty-five ordinary shares of Quoin Pharmaceuticals. The award vests over four years, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. The option expires on February 4, 2036 and is held directly by the CFO.
Quoin Pharmaceuticals director Joseph Patrick Cooper reported receiving a new stock option grant. On February 4, 2026, he was awarded options to acquire 8,141 American Depositary Shares at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals.
The options vest over four years, with 20% becoming exercisable on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. After this grant, Cooper beneficially owns 8,141 derivative securities directly.
Quoin Pharmaceuticals director granted stock options
Quoin Pharmaceuticals, Ltd. reported that director Anthony James Culverwell received a grant of share options on February 4, 2026. The award covers 21,709 American Depositary Shares (ADSs), each with an exercise price of $7.37 per ADS and no purchase price for the grant itself.
Each ADS represents thirty-five ordinary shares of the company. The option vests over four years, with 20% vesting on each of February 4, 2027, February 4, 2028 and February 4, 2029, and the remaining 40% vesting on February 4, 2030. After this transaction, Culverwell directly holds options over 21,709 ADSs.
Quoin Pharmaceuticals (QNRX) reported an equity award to its CEO and director, Michael Myers. On February 4, 2026, he received a share option covering 318,750 American Depositary Shares (ADSs) at an exercise price of $7.37 per ADS, with no purchase price paid for the grant itself.
The option becomes exercisable in four annual installments: 20% of the ADSs vest on each of February 4, 2027, 2028 and 2029, and 40% vest on February 4, 2030. The option expires on February 4, 2036 and is held directly.
Quoin Pharmaceuticals reported an equity award to its Chief Operating Officer and director Denise P. Carter. On February 4, 2026, she received a share option covering 318,750 American Depositary Shares (ADSs) with an exercise price of $7.37 per ADS, expiring on February 4, 2036.
Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. The option vests in four annual installments, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, she beneficially owns 318,750 derivative securities directly.
Quoin Pharmaceuticals director Dennis Langer received a grant of stock options linked to American Depositary Shares (ADSs). On February 4, 2026, he was awarded options to acquire 21,709 ADSs at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. The options vest over four years, with 20% vesting on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Langer beneficially owns 21,709 derivative securities directly.
Quoin Pharmaceuticals director Michael T. Sember received a new stock option grant. On February 4, 2026, he was awarded a Share Option (Right to Buy) covering 8,141 American Depositary Shares (ADSs) of Quoin Pharmaceuticals, Ltd. at an exercise price of $7.37 per ADS.
Each ADS represents thirty-five ordinary shares of the company. The option vests over four annual installments, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Sember holds 8,141 derivative securities directly.